Methods. We therefore performed this subgroup analysis of the FDCC trial, a 12-month, prospective, randomised study, comparing fixed-dose (FD) with concentration-controlled (CC) MMF dosing in paediatric and adult renal transplant recipients. Sixty-two paediatric and 839 adult de novo patients in 19 countries were randomised 1:1 to receive
Introduction
Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), has been approved for maintenance immunosuppression therapy in both adult and paediatric kidney allograft recipients. Since its introduction in the mid-1990s, it has replaced azathioprine (AZA) in the majority of immunosuppressive regimens after renal transplantation. MMF targets several steps within the activation and proliferation cascade of T and B cells-for example, inhibition of dendritic cell maturation, suppression of T lymphocyte adhesion and inhibition of inosine monophosphate dehydrogenase-therefore exerting a stronger immunosuppressive effect than AZA [1] . According to the annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, 66.5% of paediatric kidney allograft recipients are on MMF 30 days after transplantation compared with only 3.4% receiving AZA [2] . In consequence, substitution of MMF for AZA has led to a significant reduction of the acute rejection rate in adult and paediatric kidney allograft recipients alike [3] [4] [5] [6] [7] . Common MMF-related side effects comprise infections and myelosuppression, namely anaemia and leucocytopaenia, as well as gastrointestinal symptoms such as abdominal pain, diarrhoea and nausea [4, 6, 8] . To date, only one small retrospective single-centre comparative study has indicated a higher incidence of adverse events and a lower tolerability in children and adolescents than in adults [9] . Reports on large-scale, prospective investigations using a comparable MMF-based immunosuppressive regimen and similar diagnostic criteria within the same study according to Good Clinical Practice guidelines in adult and paediatric patients are lacking. Recently, a prospective, multicentre, randomised trial was conducted to investigate the added value of therapeutic drug monitoring of MPA by comparing fixed-dose (FD) with concentration-controlled (CC) MMF therapy in both adult and paediatric de novo kidney allograft recipients [10] . In this paper, we present a subgroup analysis of that study, which focuses on the comparison of the efficacy and tolerability of MMF between adult and paediatric renal transplant patients.
Materials and methods

Patients and study design
This subgroup analysis was performed in the framework of the FDCC study which has been reported previously [10] . In a 12-month, multicentre, open-label, randomised trial (study number: NCT00166244; https:// register.clinicaltrials.gov), we compared the efficacy and safety profile of MMF between adult and paediatric kidney allograft recipients who were treated with a similar immunosuppressive protocol. Eligible patients from 67 centres in 19 countries (Europe, South America, Canada, Asia and Australia) were centrally randomised at the ratio of 1:1 to be administered with fixed-dose MMF or an MMF dose based on MPA plasma concentration measurements (concentration-controlled group). Inclusion and exclusion criteria have been published previously [10] . In brief, eligible study subjects were adult and paediatric patients, aged ≥2 years, who had received an AB0-compatible single-organ renal transplant from a living or deceased donor. Exclusion criteria comprised use of prohibited immunosuppressants, active or history of malignancy, haematological abnormalities, HIVor HBV infection, panel-reactive antibodies (PRA) >50% within 6 months prior to study entry, liver disorder and active peptic ulcer disease [10] . The respective investigations were conducted in accordance with the Helsinki Declaration and approved by the ethics committee of each contributing centre. Written informed consent of patients, their parents or guardians was obtained before initiation of any study-related procedure. The present subgroup analysis was performed at the end of the main FDCC trial and thus does not take into account randomisation. Since no significant difference was revealed between the fixed-dose and concentration-controlled cohorts of the main FDCC trial [10] , we pooled the data of both cohorts for the present subgroup analysis.
Immunosuppression and study procedures
The initial MMF dose was 1000 mg in adults and 600 mg/m² body surface area (BSA) in paediatric recipients. Thereafter, adult and paediatric patients in the fixed-dose group received 1000 mg, respectively, 600 mg/m² BSA twice daily for the first 30 days post-transplant and, afterwards, a centredefined maintenance dose. In the concentration-controlled group, patients were administered the same initial MMF dose as the fixed-dose cohort. After that, their MMF dosage was adjusted to achieve target MPA-abbreviated area-under-the-curve (AUC) levels between 30 and 60 mg/h/L. Before, 30 and 120 min after MMF administration, MPA concentrations were measured by means of EMIT assay (Dade-Behring, Newark, DE) or highperformance liquid chromatography, which, in turn, served to calculate the MPA-abbreviated AUC, based on four different algorithms for adult or paediatric patients on tacrolimus (Tac) or cyclosporine microemulsion (CsA) [10] [11] [12] [13] . Concomitant immunosuppression consisted of a calcineurin inhibitor, namely Tac or CsA, and corticosteroids, administered in line with centre practice.
Study end points of the main trial have already been reported in detail [10] . The present subgroup analysis focused on efficacy and safety parameters of MMF treatment in paediatric vs. adult renal transplant recipients. Aside from patient and graft survival, the rates of presumed acute rejection episodes (AREs), biopsy-proven acute rejections (BPARs) and treated AREs were compared between paediatric and adult kidney allograft recipients. Presumed acute rejections were defined as not biopsyproven acute rejections, suspected on clinical grounds and for which anti-rejection therapy was given. Additionally, renal transplant function was evaluated in both patient cohorts, using the estimated glomerular filtration rate (eGFR) according to Cockcroft and Gault for adults [14] or according to Schwartz for children and adolescents [15] . Five pre-specified adverse events were of particular interest for this study, due to their possible association with MMF treatment: anaemia (haemoglobin concentration <11.3 g/dL after day 28), leucocytopaenia (total leucocyte count <3000/μL), thrombocytopaenia (total thrombocyte count <100/nL), diarrhoea (defined as more than four loose stools per day) and weight loss (>10% loss of body weight at transplantation). Furthermore, we compared the percentage of adverse events causing interruption of MMF therapy between paediatric and adult kidney allograft recipients.
Statistical analyses
Data from this subgroup study were analysed based on version 8.2 of the SAS statistical package. The intention-to-treat population was used to compare the MMF efficacy and safety profile in paediatric (n = 62) and adult patients (n = 839). Since intention-to-treat analysis may not be appropriate for analysis of adverse events, we performed an additional robustness analysis of the per-protocol population (n = 57 paediatric and n = 770 adult patients), which did not reveal any significant differences compared with the intention-to-treat analysis and is therefore not separately shown. Unless stated otherwise, results for continuous variables are expressed as mean together with the associated two-sided 95% CI derived using the t-distribution, while results for categorical outcomes are expressed as the number and percentage of patients with the observed outcome of interest. In addition, two-sided exact 95% CI derived by means of the Clopper-Pearson method for a binomial proportion is also provided for binary outcomes. P-values for categorical variables were determined on the basis of Fisher's exact test, while P-values for comparison of MMF dosage, MPA levels and MPA-AUCs were derived using the Wilcoxon rank sum test. Two-tailed P < 0.05 was considered statistically significant.
Results
Between May 2003 and April 2006, 62 paediatric (mean age 11.4 ± 4.5 years) and 839 adult (mean age 48.0 ± 13.3 years) renal transplant recipients were recruited for Fig. 1 . Assignment of paediatric and adult renal allograft recipients to concentration-controlled (CC) or fixed-dose (FD) mycophenolate mofetil, and reasons for premature withdrawal from the study.
Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial the trial. Thirty-one children and 418 adults were randomised into the concentration-controlled group, and 31 children and 421 adults into the fixed-dose group (Figure 1) . Figure 1 depicts the trial profile including drop-outs and reasons for premature withdrawal from the study. Baseline characteristics and concomitant immunosuppressive medication of the paediatric and adult study populations are shown in Table 1 . While distribution of gender, transplant history and PRA levels were comparable between the patient cohorts, the type of primary renal diseases leading to end-stage renal disease was typically distinct between the two groups, with a higher prevalence of structural abnormalities of the urinary tract in children and a predominance of diabetes mellitus and arterial hypertension in adults (data not shown). Paediatric patients received their allograft from younger donors than adults (Table 1 ). In this particular cohort, living donation was performed more often in adult renal transplant recipients, resulting in a shorter cold ischaemia time in adults (Table 1) . Paediatric patients were given anti-lymphocyte antibody induction (anti-IL-2 receptor antibodies and mono-or polyclonal T-cell antibodies) therapy more frequently than adults (Table 1) .
Efficacy
Overall patient and graft survival were excellent in paediatric and adult renal transplant recipients alike (Table 2) . Neither was there a significant difference in the rate or severity of BPAR between paediatric and adult patients nor in the incidence of treated acute rejections (Table 2) . However, both paediatric and adult patients under Tac had significantly less treated acute rejections than patients under CsA therapy (Table 2) . Similar to adult patients, Tac-treated children and adolescents had a numerically lower rate of BPARs than patients on CsA, but due to the low number of observations, this difference did not reach statistical significance. No significant difference was observed in the rate or severity of BPAR between paediatric patients receiving fixed-dose MMF and those on concentration-controlled MMF (data not shown). Whereas no paediatric patients completely abandoned MMF therapy during the 12-month study period, 61 [7.3% (CI 5.6-9.2)] adult kidney allograft recipients completely abandoned MMF treatment.
Transplant function, expressed as eGFR, is illustrated in Figure 2 . Mean eGFR was comparable between paediatric and adult renal allograft recipients over the entire study period.
Safety profile
Safety of MMF therapy was evaluated based on the occurrence of adverse events, including opportunistic infections and malignancies. Figure 3) . Younger children below 6 years of age showed a numerically higher frequency of leucocytopaenia, diarrhoea and weight loss than older ones and adults ( Figure 3 ). While the frequency of diarrhoea was comparable (P = 0.56) between CsA-(36.4%) and Tac-treated (27.5%) paediatric recipients, in the adult population, significantly more Tac-treated (34.0%) patients developed diarrhoea than patients on CsA (17.2%, P < 0.0001). In general, the percentage of patients who experienced an adverse event causing interruption of MMF therapy were numerically lower in paediatric patients [4.8% (CI 1.0-13.5)] than in adults [12.5% (CI 10.4-14.9)] (Figure 3 ). Both paediatric and adult patients developed a similar pattern of opportunistic infections (Table 3) , with Cytomegalovirus being the most common pathogen (64.7%), followed by herpes simplex virus (20.9%) and VZV (14.9%). Fungal infections were mainly due to Candida species (12.9%); Pneumocystis jirovecii pneumonia occurred in six patients (2.4%) altogether (Table 3) . While 1.3% (11/839) of adult patients developed a malignant disorder, none of the paediatric recipients suffered a malignancy throughout the study period.
Pharmacokinetic analyses
MMF dosage (body surface area-adjusted in paediatrics) and MPA exposure were similar in the concentrationcontrolled and the fixed-dose group of both the paediatric and the adult population (data not shown). Only at study month 6, significantly more paediatric patients in the concentration-controlled group reached the MPA-AUC target range between 30 and 60 mg/h/L than in the fixed-dose group (data not shown).
In the subgroup of paediatric kidney allograft recipients, mean daily MMF doses were significantly higher in CsAthan in Tac-treated patients (Table 4) . Mean MPA pre-dose concentrations were significantly lower in CsA-treated than in Tac-treated patients (Table 4 ). In addition, CsAtreated children had a lower MPA exposure, as estimated by the abbreviated MPA-AUC profile throughout the 12-month study period, than those on Tac (Table 4) .
Discussion
This is the first study that investigated the efficacy and safety profile of MMF in paediatric renal transplant recipients compared with adults within the same prospective study protocol. The overall efficacy and tolerability of MMF in paediatrics were comparable with adults. Specifically, the rates of BPAR, as well as presumed and treated AREs were comparable between paediatric and adult kidney allograft recipients, with mild-and moderate-grade rejections being the most common ones ( Table 2 ). The incidence of treated acute rejections in both paediatric and adult patients on Tac-based immunosuppression was significantly lower than in those on CsA-based immunosuppressive therapy (Table 2 ). These findings are consistent with the results of the Symphony Study, where the rate of presumed and treated AREs was significantly lower in Table 2 Comparison between adult Tac-and CsA-treated patients (P < 0.001). Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial adult patients receiving low-dose Tac than in recipients of low-dose or standard-dose CsA (17.2% vs. 29.5% and 32.8%, respectively, P < 0.001) [16] . It is noteworthy, however, that the MPA exposure in the present study was significantly lower in CsA-treated paediatric and adult patients than in Tac-treated patients, due to the fact that CsA decreases the enterohepatic recycling of MPA by inhibiting the MRP2-mediated glucuronide transport of 7-O-MPAG into bile, thus reducing systemic MPA exposure [16, 17] . The lower rate of treated acute rejections in Tac-receiving patients might therefore partly be attributable to the concurrent higher MPA exposure. In our study, the MMF safety profile in paediatric patients was, in general, comparable with adult renal transplant recipients. However, children <6 years exhibited a numerically higher frequency of leucocytopaenia (20%), diarrhoea (40%) and weight loss (10%) than older children and adults. These data are comparable with those of the MMF suspension trial, a prospective single-arm study among 100 paediatric renal transplant patients under MMF treatment in combination with CsA and corticosteroids, in which an incidence of leucocytopaenia of 30.3% and of diarrhoea of 87.9% in children below 6 years of age was observed [4] . The potentially higher incidence of diarrhoea in young children might be related to a higher sensitivity of the gut mucosa towards the anti-proliferative effect of MMF, which might be superimposed by their greater susceptibility to viral gastroenteritides enhanced by immunosuppressive therapy. An explanation for the potentially increased incidence of leucocytopaenia in young children might be their greater susceptibility to viral infections, owing to the absence of prior natural immunity, leading secondarily to leucocytopaenia. In addition, weight loss occurred more frequently in children < 6 years than in older paediatric and adult patients. This might be attributable, at least partly, to their higher frequency of infectious and non-infectious diarrhoea. Also, isolated MMF-related weight loss in the absence of other gastrointestinal symptoms, which resolved completely after conversion from MMF to AZA, has seldom been described.
Interestingly, none of the paediatric patients involved in our study completely abandoned MMF therapy during the Fig. 3 . Comparison of specific adverse events in children younger than 6 years of age (black bars), children and adolescents between 6 and 18 years (striped bars), the entire paediatric (grey bars), and the entire adult study population (white bars). first post-transplant year. In addition, under an equivalent MMF dose, drug-related adverse events leading to intermittent interruption of MMF treatment occurred in children and adolescents numerically less frequently (4.8%) than in adults (12.5%). On the other hand, the rate of MMF discontinuation in paediatric patients in the MMF suspension trial (10%) [4] is comparable with the rate in adults observed in the current study. The only study that found a higher rate of MMF-related side effects in paediatric vs. adult renal transplant recipients is a retrospective single-centre analysis in a small cohort of patients (22 paediatric and 37 adult renal transplant recipients) with random inclusion criteria [9] . Taken altogether, the overall MMF tolerability in paediatric patients under an equivalent MMF dosage and immunosuppressive protocol appears to be comparable with that in adults.
According to the present subgroup analysis, renal transplant function, expressed as eGFR, was similar in paediatric and adult renal transplant recipients during the entire 1-year study period ( Figure 2 ) and comparable with that observed in the Symphony Study [18] : at 1 year after engraftment, mean eGFR was 65.4 ± 27.0 mL/min/1.73 m² in patients treated with low-dose Tac, MMF and steroids compared with 59.4 ± 25.1 mL/min/1.73 m² in patients under low-dose CsA/MMF/steroids and to 57.1 ± 25.1 mL/min/ 1.73 m² in recipients undergoing standard-dose CsA/MMF/ steroids therapy [18] .
As pointed out before, a potential limitation of this study may be its design as a comparative subgroup analysis, which was not pre-specified in the statistical analysis plan of the FDCC trial. Therefore, any differences of our subgroup study should be interpreted cautiously, and we cannot draw firm conclusions from our results. On the other hand, this is the first prospective study ever published in which paediatric and adult patients were treated on the basis of the same immunosuppressive protocol using similar diagnostic criteria according to Good Clinical Practice guidelines. We therefore feel that our observations do provide clinically relevant information.
In conclusion, this subgroup analysis of the large-scale FDCC trial suggests that the overall efficacy and tolerability of MMF in paediatrics appear to be comparable with that in adults. Further studies are needed to validate these results.
